How can early-phase CROs stay afloat in a changing market?

Aug 19 2013

FierceCRO

They don't make compounds like they used to--or at least at the same rate. And with fewer and fewer early-stage molecules moving through pipelines, CROs that used to count on early-phase business are having to get creative. For Charles River Laboratories, which specializes in preclinical services, the key to success in an evolving market is delivering consistent quality.

Click here to read full article from FierceCRO.